Patent classifications
A01N1/021
EX VIVO ORGAN TREATMENT WITH PEG-PHOSPHOLIPID MOLECULES
An organ graft is ex vivo treated by ex vivo infusing a solution comprising PEG-phospholipid molecules into a vascular system of the organ graft. The solution comprising PEG-phospholipid molecules is ex vivo incubated in the vascular system to enable coating of at least a portion of the endothelial lining of the vascular system with the PEG-phospholipid molecules while keeping the organ or the part of the organ submerged in an organ preservation solution comprising PEG-phospholipid molecules. Such an ex vivo treatment of organ grafts with PEG-phospholipid protected the organ grafts against thromboinflammation and reduced blood pressure drops that otherwise occurred when reperfusing the organ graft in the recipient.
METHODS, SYSTEMS AND COMPOSITIONS FOR NORMOTHERMIC EX VIVO PRESERVATION OF INTACT ORGANS
The invention provides a system for normothermic, ex vivo restoration and preservation of an intact mammalian brain, and other organs. In certain aspects, the system is capable of preserving a brain as well as other organs, maintaining cellular integrity and cellular function for hours post mortem or after global ischemia. The invention also provides synthetic brain perfusate formulations, including a novel brain perfusion medium (BPM), which are able to reduce reperfusion injury, stimulate recovery from hypoxia, prevent edema and metabolically support the energy needs of brain function.
UMBILICAL TISSUE COMPOSITIONS AND METHODS OF USE
Disclosed are compositions comprising umbilical tissue, wherein the umbilical tissue comprises one or more engineered channels. Also disclosed are compositions comprising a previously cryopreserved umbilical tissue, wherein after cryopreservation and subsequent thawing the umbilical tissue comprises: a) viable cells native to the umbilical tissue; b) tissue integrity of native umbilical tissue; c) one or more growth factors that are native to the umbilical tissue; and d) depleted amounts of one or more types of functional immunogenic cells. Disclosed are methods of producing compositions comprising umbilical tissue, wherein the umbilical tissue comprises one or more engineered channels. Also disclosed are methods of treating damaged tissue comprising administering to the site of the damaged tissue compositions comprising umbilical tissue, wherein the umbilical tissue comprises one or more engineered channels.
Storage media and powder formulations for avulsed teeth and explanted tissues comprising fibroblasts
Disclosed herein are methods and compositions for preserving avulsed teeth and/or explanted tissue. The disclosed methods for preserving avulsed teeth and/or explanted tissue typically include placing the avulsed teeth and/or explanted tissue in a preservation solution comprising at least about 2.75 g/L sugar. Suitable explanted tissues for the disclosed methods may include explanted tissues comprising fibroblasts, such as dental tissue and/or oral tissue. The preservation solution of the disclosed preservation methods may include additional components which may include but are not limited to inorganic salts, amino acids, vitamins, and buffering agents. The preservation solution may be prepared from a powder formulation having a long shelf-life.
METHOD FOR VITRIFICATION AND THAWING OF OOCYTE OF CANINE AND FROZEN-THAWED OOCYTE PRODUCED USING THE SAME
The present invention relates to a method for vitrification and thawing of oocytes of animals for somatic cell cloning. More specifically, the present disclosure relates to a method for vitrification and thawing of canine oocytes, and to thus produced frozen-thawed oocytes. In a conventional approach of the vitrification-frozen oocyte production for the dog, an estrous cycle may not coincide with an experimental schedule. However, the method for vitrification and thawing of the canine oocyte according to the present disclosure and the resulting frozen-thawed oocyte allows an experimental schedule to coincide with the estrous cycle, resulting in high nuclear transfer and fertilization effects.
OXYGENATION MEDIA FOR EX-VIVO PRESERVATION OF ORGANS AND TISSUES
Oxygenation constituents and finished oxygenation media, as well as methods of making oxygenation constituents and finished oxygenation media are provided. The oxygenation constituents comprise a hemoglobin preparation, and a red blood cell preparation. The oxygenation constituents comprise from about 10% to about 99% by weight hemoglobin of the hemoglobin preparation and the balance by weight hemoglobin of the oxygenation constituents comprise a red blood cell preparation. The finished oxygenation media comprise the oxygenation constituents and one or more other ingredients such as a diluent, or excipient. The finished oxygenation media can be used to ex-vivo preserve organs or tissue.
PORTABLE OXYGEN SOURCE WITH PERFUSION SYSTEM
The present disclosure includes a system to preserve tissue and associated methods. The system can include a portable oxygen source to provide oxygen and apply a pressure gradient to a flow of the oxygen, an organ preservation system having an inlet to fluidly couple to vasculature of the tissue, and an oxygen line to fluidly couple the portable oxygen source to the organ preservation system at the inlet, wherein the portable oxygen source is to apply the pressure gradient to pump fluid containing the oxygen through the organ preservation system.
METHODS FOR THE PRESERVATION OF REAGENT RED BLOOD CELLS USING CARBON MONOXIDE
This application provides methods, compositions, and kits for use blood group determination and the preparation of improved red blood cell containing reagents for use in blood typing of blood prior to its use in transfusion medicine.
Method for living tissue preservation
A method for platelet preservation comprising placing a composition comprising platelets in a gas mixture comprising xenon and oxygen under pressure of about 0-10 Bars at a first temperature of about 18° C.-37° C. for a first period of time, and then subsequently cooling the composition to a second temperature of about 0,1° C.-6° C., and holding the composition under the pressure and in the second temperature for a second period of time.
Solution for preserving and/or rinsing an organ to be transplanted
This invention relates to an aqueous solution for preserving and rinsing organs to be transplanted comprising: sodium (Na+) ions at a concentration between 30 and 150 mmol.Math.L.sup.−1; potassium ions (K+) at a concentration between 10 and 40 mmol.Math.L.sup.−1; polyethylene glycol with a molecular weight of 35,000 g.Math.mol-1 (PEG 35000) at a concentration between 2 and 5 g.Math.L.sup.−1.